Earnings call transcript: Precipio tops $7 million in Q2 2025 as growth turns profitable

Precipio Diagnostics reported a record-breaking second quarter in 2025, with revenue reaching $7.0 million, a 22.8% increase from the previous year. The company achieved positive adjusted EBITDA and generated $700,000 in operating cash flow. Shares closed at $23.9, up 1.7% from the prior session and maintaining a steady trading price after hours.

Management highlighted the growing popularity of the Rapid AML Panel and an expanding commercial pipeline. Revenue from the product segment increased to $900,000, accounting for 12.9% of total sales, surpassing previous records. The quarter marked the first time Precipio exceeded $7 million in revenue, with a market capitalization of $42.84 million.

The company's gross profit margin stands at 44.1%. Despite the positive results, no EPS or revenue forecast was provided for the quarter. Precipio's shares have shown resilience, trading above its 52-week low of $13.8 but below its 52-week high of $33.63. The company expects continued revenue growth in the second half of 2026, emphasizing partnerships with major distributors and expanding its sales approach.

Management attributed the strong performance to a focus on operating leverage and the benefits of their laboratory investments.